Our client had concerns as to whether the clinical end-points in their phase III trial were relevant...
Read moreOur clients have been developing new drugs for crowded, rapidly evolving therapy areas, with uncerta...
Read moreOur client was seeking to launch and in-licensed product in the EU, following launch in the US.
Read moreOur client wanted to organise an advisory board to seek guidance from a range of stakeholders within...
Read moreOur client wanted to gain an understanding of payer willingness to pay and determine the likely clin...
Read moreOur client required focused payer value messages for their orphan drug as payers were not recognizin...
Read moreOur client wanted to gain a better understanding of current and forthcoming policy measures affectin...
Read moreDevelopment and submission of payer communication materials and pricing and reimbursement dossiers f...
Read moreOncology products, advanced therapy medicinal products (ATMPs) and medical devices are entering the ...
Read moreWe explore what the joint clinical assessment (JCA) is, its process and what future developments may...
Read more